BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 23329387)

  • 1. Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.
    Hummel TR; Chow LM; Fouladi M; Franz D
    Paediatr Drugs; 2013 Feb; 15(1):29-42. PubMed ID: 23329387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibitors in children with malignant gliomas.
    Herrington B; Kieran MW
    Pediatr Blood Cancer; 2009 Sep; 53(3):312-7. PubMed ID: 19434732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
    Chen R; Cohen AL; Colman H
    Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Salvage Treatment Strategies for Younger Children (<10 y of Age) With Progressive Low-grade Glioma After Initial Chemotherapy in North America: A Web-based Survey.
    Moorman B; Barbour M; Huang MA
    J Pediatr Hematol Oncol; 2021 Jan; 43(1):e141-e145. PubMed ID: 33235141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasion is not an independent prognostic factor in high-grade glioma.
    Narayana A; Perretta D; Kunnakkat S; Gruber D; Golfinos J; Parker E; Medabalmi P; Zagzag D; Pat Eagan RN; Gruber M
    J Cancer Res Ther; 2011; 7(3):331-5. PubMed ID: 22044816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspective.
    Finlay JL; Zacharoulis S
    J Neurooncol; 2005 Dec; 75(3):253-66. PubMed ID: 16195805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management.
    Sturm D; Pfister SM; Jones DTW
    J Clin Oncol; 2017 Jul; 35(21):2370-2377. PubMed ID: 28640698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of high-grade glioma in children and adolescents.
    MacDonald TJ; Aguilera D; Kramm CM
    Neuro Oncol; 2011 Oct; 13(10):1049-58. PubMed ID: 21784756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
    Kyritsis AP; Levin VA
    Cancer Chemother Pharmacol; 2011 May; 67(5):971-83. PubMed ID: 21442438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab in recurrent high-grade pediatric gliomas.
    Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
    Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic therapy for high-grade gliomas.
    Chamberlain MC; Raizer J
    CNS Neurol Disord Drug Targets; 2009 Jun; 8(3):184-94. PubMed ID: 19601816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy in the treatment of high grade gliomas.
    Lonardi S; Tosoni A; Brandes AA
    Cancer Treat Rev; 2005 Apr; 31(2):79-89. PubMed ID: 15847978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy in pediatric low-grade glioma.
    Kilday JP; Bartels UK; Bouffet E
    Curr Neurol Neurosci Rep; 2014 Apr; 14(4):441. PubMed ID: 24604059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
    Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
    Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY
    J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines.
    Alexandru O; Sevastre AS; Castro J; Artene SA; Tache DE; Purcaru OS; Sfredel V; Tataranu LG; Dricu A
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature.
    Lombardi G; Zustovich F; Farina P; Polo V; Farina M; Della Puppa A; Bertorelle R; Gardiman MP; Berti F; Zagonel V
    Anticancer Drugs; 2012 Aug; 23(7):749-53. PubMed ID: 22382388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalamic high-grade gliomas in children: a distinct clinical subset?
    Kramm CM; Butenhoff S; Rausche U; Warmuth-Metz M; Kortmann RD; Pietsch T; Gnekow A; Jorch N; Janssen G; Berthold F; Wolff JE
    Neuro Oncol; 2011 Jun; 13(6):680-9. PubMed ID: 21636712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
    Chamberlain MC
    Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.